EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Subscribe To Our Newsletter & Stay Updated